Project Grant R01CA316597
Award Date 7/24/26
Completion Date 6/30/31
Dollars Obligated $667K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Cancer Institute awarded the University of Southern California $426,828 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026, to identify potent anti-human CD1D antibodies and examine synergistic iNKT cell activation for metastatic melanoma immunotherapy. The project leverages novel human CD1D-knockin mouse models expressing human iNKT T cell receptor alpha chains to overcome prior translational barriers in anti-CD1D antibody development. Work aims to screen...
- The National Cancer Institute awarded the University of California, Los Angeles $653,568 on July 1, 2026, through the Cancer Treatment Research program (CFDA 93.395) to conduct research on enhancing antitumor immunity through pharmacologic modulation of T-cell-mediated cytotoxicity. The research addresses a bottleneck in immunotherapy: naturally occurring T cells targeting tumor-associated antigens or neoantigens often exhibit low to intermediate affinity and weak antitumor activity, and...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $730,097 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms by which chronic inflammation suppresses T-cell immunity in gastric adenocarcinoma. The research addresses how persistent innate inflammation impairs T-cell surveillance in gastric tumors, which exhibit minimal response to immune checkpoint blockade despite high inflammation levels. The project applies...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of California Irvine $648,626 on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy. The funded research examines why PD-1 checkpoint inhibitors fail in most cancer patients despite providing durable benefits in approximately 40 percent of patients with metastatic melanoma and...
- The National Cancer Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Trustees of Columbia University in the City of New York $630,089 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds research to characterize the molecular mechanisms by which the DNA translocase SMARCAL1 suppresses anti-tumor immune responses and to identify other DNA damage response factors that function analogously to...
- The National Cancer Institute awarded $694,015 to the Beckman Research Institute of the City of Hope on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify and target cancer immune evasion signals against macrophage surveillance. The research investigates mechanisms by which cancer cells evade immune detection, with focus on tumor-associated macrophages and their capacity to recognize and eliminate cancer cells through programmed cell removal. The project...
- The National Cancer Institute of the Department of Health and Human Services awarded the Beckman Research Institute of the City of Hope $733,864 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify and characterize stimulatory immune checkpoints regulating macrophage-mediated programmed cell removal in tumor immunosurveillance. The research uses high-throughput CRISPR-based screening to investigate how a novel stimulatory innate immune checkpoint interacts with...
- The National Institutes of Health National Cancer Institute awarded the University of Southern California $479,234 on May 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate nonsense-mediated mRNA decay mechanisms in cancer biology. The project explores how nonsense-mediated mRNA decay (NMD) functions beyond its conventional role of degrading faulty transcripts, with three specific aims: decode gene dependencies in cancer cell lines using NMD residual signatures from...
- The National Cancer Institute awarded a $1.21 million cooperative agreement to The Leland Stanford Junior University on August 7, 2026, to support research on tumor-immune coevolution during metastatic progression under the Cancer Biology Research program (CFDA 93.396). The research investigates how tumors and lymphocytes undergo reciprocal adaptive evolution throughout metastasis, with focus on mechanisms by which early-stage metastatic tumors exploit immune education within lymph nodes to...
- The National Institutes of Health National Cancer Institute awarded the University of Southern California $581,548 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the therapeutic mechanisms of targeting WRN in microsatellite-instable colorectal cancer. The research will delineate mechanisms by which Werner helicase inhibition triggers cell death in MSI colorectal cancer cells and elucidate the immunological effects of that cell death. The work focuses on...